Zacks
BioLife Solutions, Inc. (BLFS) Surpasses Q4 Earnings and Revenue Estimates
📈
AI Sentiment
Highly Positive
8/10
- Home
- MGNX
MGNX
MacroGenics Inc.
as of 03-03-2026 3:54pm EST
$1.88
$0.06
-3.35%
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | Rockville |
| Market Cap: | 115.8M | IPO Year: | 2013 |
| Target Price: | $3.20 | AVG Volume (30 days): | 533.9K |
| Analyst Decision: | Hold | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.96 | EPS Growth: | -613.33 |
| 52 Week Low/High: | $0.99 - $2.48 | Next Earning Date: | N/A |
| Revenue: | $149,962,000 | Revenue Growth: | 155.26% |
| Revenue Growth (this year): | -14.86% | Revenue Growth (next year): | -50.75% |
| P/E Ratio: | -2.03 | Index: | N/A |
| Free Cash Flow: | -72079000.0 | FCF Growth: | N/A |
AI-Powered MGNX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 65.41%
65.41%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Earnings Call Transcripts for MacroGenics Inc. (MGNX)
Historical SEC 8-K earnings filings with full transcript text
2025 Q3 Q3 2025 Earnings
8-K
Filed November 12, 2025
2025
Q3
Q3 2025 Earnings
8-KFiled November 12, 2025
Nov 12, 2025 0001125345-25-000109
mgnx-202511120001125345FALSE00011253452025-11-122025-11-12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 12, 2025 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 9704 Medical Center Drive Rockville,Maryland20850 (Address of Principal Executive Offices)(Zip Code) Registrant's telephone number, including area code: (301) 251-5172 Not applicable (Former Name or Former Address, if Changed Since Last Report) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.01 per share MGNXNasdaq Global Select Market Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02 Results of Operations and Financial Condition On November 12, 2025, MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the quarter ended September 30, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit NumberDescription of Exhibit 99.1 Press Release dated November 12, 2025 104Cover Page Interactive Data (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 12, 2025MACROGENICS, INC. By: /s/ Jeffrey Peters Jeffrey Peters Senior Vice President and General Counsel
2025 Q2 Q2 2025 Earnings
8-K
Filed August 14, 2025
2025
Q2
Q2 2025 Earnings
8-KFiled August 14, 2025
Aug 14, 2025 0001125345-25-000100
mgnx-202508140001125345FALSE00011253452025-08-142025-08-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2025 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 9704 Medical Center Drive Rockville,Maryland20850 (Address of Principal Executive Offices)(Zip Code) Registrant's telephone number, including area code: (301) 251-5172 Not applicable (Former Name or Former Address, if Changed Since Last Report) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.01 per share MGNXNasdaq Global Select Market Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02 Results of Operations and Financial Condition On August 14, 2025, MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the quarter ended June 30, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit NumberDescription of Exhibit 99.1 Press Release dated August 14, 2025 104Cover Page Interactive Data (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 14, 2025MACROGENICS, INC. By: /s/ Jeffrey Peters Jeffrey Peters Senior Vice President and General Counsel
2025 Q1 Q1 2025 Earnings
8-K
Filed May 13, 2025
2025
Q1
Q1 2025 Earnings
8-KFiled May 13, 2025
May 13, 2025 0001125345-25-000054
mgnx-202505130001125345FALSE00011253452025-05-132025-05-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2025 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 9704 Medical Center Drive Rockville,Maryland20850 (Address of Principal Executive Offices)(Zip Code) Registrant's telephone number, including area code: (301) 251-5172 Not applicable (Former Name or Former Address, if Changed Since Last Report) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.01 per share MGNXNasdaq Global Select Market Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02 Results of Operations and Financial Condition On May 13, 2025, MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the quarter ended March 31, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit NumberDescription of Exhibit 99.1 Press Release dated May 13, 2025 104Cover Page Interactive Data (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 13, 2025MACROGENICS, INC. By: /s/ Jeffrey Peters Jeffrey Peters Senior Vice President and General Counsel
2024 Q4 Q4 2024 Earnings
8-K
Filed March 20, 2025
2024
Q4
Q4 2024 Earnings
8-KFiled March 20, 2025
Mar 20, 2025 0001125345-25-000043
mgnx-202503200001125345FALSE00011253452025-03-202025-03-20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 20, 2025 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 9704 Medical Center Drive Rockville,Maryland20850 (Address of Principal Executive Offices)(Zip Code) Registrant's telephone number, including area code: (301) 251-5172 Not applicable (Former Name or Former Address, if Changed Since Last Report) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.01 per share MGNXNasdaq Global Select Market Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02 Results of Operations and Financial Condition On March 20, 2025, MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the year ended December 31, 2024. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit NumberDescription of Exhibit 99.1 Press Release dated March 20, 2025 104Cover Page Interactive Data (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 20, 2025MACROGENICS, INC. By: /s/ Jeffrey Peters Jeffrey Peters Senior Vice President and General Counsel
2024 Q3 Q3 2024 Earnings
8-K
Filed November 5, 2024
2024
Q3
Q3 2024 Earnings
8-KFiled November 5, 2024
Nov 5, 2024 0001125345-24-000161
mgnx-202411050001125345FALSE00011253452024-05-092024-05-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 5, 2024 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 9704 Medical Center Drive Rockville,Maryland20850 (Address of Principal Executive Offices)(Zip Code) Registrant's telephone number, including area code: (301) 251-5172 Not applicable (Former Name or Former Address, if Changed Since Last Report) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.01 per share MGNXNasdaq Global Select Market Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02 Results of Operations and Financial Condition On November 5, 2024, MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the quarter ended September 30, 2024. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit NumberDescription of Exhibit 99.1 Press Release dated November 5, 2024 104Cover Page Interactive Data (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 5, 2024MACROGENICS, INC. By: /s/ Jeffrey Peters Jeffrey Peters Senior Vice President and General Counsel
2024 Q2 Q2 2024 Earnings
8-K
Filed August 6, 2024
2024
Q2
Q2 2024 Earnings
8-KFiled August 6, 2024
Aug 6, 2024 0001125345-24-000149
mgnx-202408060001125345FALSE00011253452024-05-092024-05-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 6, 2024 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 9704 Medical Center Drive Rockville,Maryland20850 (Address of Principal Executive Offices)(Zip Code) Registrant's telephone number, including area code: (301) 251-5172 Not applicable (Former Name or Former Address, if Changed Since Last Report) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.01 per share MGNXNasdaq Global Select Market Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02 Results of Operations and Financial Condition On August 6, 2024, MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the quarter ended June 30, 2024. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit NumberDescription of Exhibit 99.1 Press Release dated August 6, 2024 104Cover Page Interactive Data (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 6, 2024MACROGENICS, INC. By: /s/ Jeffrey Peters Jeffrey Peters Senior Vice President and General Counsel
2024 Q1 Q1 2024 Earnings
8-K
Filed May 9, 2024
2024
Q1
Q1 2024 Earnings
8-KFiled May 9, 2024
May 9, 2024 0001125345-24-000091
mgnx-202405090001125345FALSE00011253452024-05-092024-05-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2024 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 9704 Medical Center Drive Rockville,Maryland20850 (Address of Principal Executive Offices)(Zip Code) Registrant's telephone number, including area code: (301) 251-5172 Not applicable (Former Name or Former Address, if Changed Since Last Report) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.01 per share MGNXNasdaq Global Select Market Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02 Results of Operations and Financial Condition On May 9, 2024, MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the quarter ended March 31, 2024. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit NumberDescription of Exhibit 99.1 Press Release dated May 9, 2024 104Cover Page Interactive Data (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 9, 2024MACROGENICS, INC. By: /s/ Jeffrey Peters Jeffrey Peters Senior Vice President and General Counsel
2023 Q4 Q4 2023 Earnings
8-K
Filed March 7, 2024
2023
Q4
Q4 2023 Earnings
8-KFiled March 7, 2024
Mar 7, 2024 0001125345-24-000061
mgnx-202403070001125345FALSE00011253452024-03-072024-03-07 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 7, 2024 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 9704 Medical Center Drive Rockville,Maryland20850 (Address of Principal Executive Offices)(Zip Code) Registrant's telephone number, including area code: (301) 251-5172 Not applicable (Former Name or Former Address, if Changed Since Last Report) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.01 per share MGNXNasdaq Global Select Market Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02 Results of Operations and Financial Condition On March 7, 2024, MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the year ended December 31, 2023. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit NumberDescription of Exhibit 99.1 Press Release dated March 7, 2024 104Cover Page Interactive Data (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 7, 2024MACROGENICS, INC. By: /s/ Jeffrey Peters Jeffrey Peters Senior Vice President and General Counsel
2023 Q3 Q3 2023 Earnings
8-K
Filed November 6, 2023
2023
Q3
Q3 2023 Earnings
8-KFiled November 6, 2023
Nov 6, 2023 0001125345-23-000125
mgnx-202311060001125345FALSE00011253452023-11-062023-11-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 6, 2023 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 9704 Medical Center Drive Rockville,Maryland20850 (Address of Principal Executive Offices)(Zip Code) Registrant's telephone number, including area code: (301) 251-5172 Not applicable (Former Name or Former Address, if Changed Since Last Report) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.01 per share MGNXNasdaq Global Select Market Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02 Results of Operations and Financial Condition On November 6, 2023, MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the quarter ended September 30, 2023. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit NumberDescription of Exhibit 99.1 Press Release dated November 6, 2023 104Cover Page Interactive Data (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 6, 2023MACROGENICS, INC. By: /s/ Jeffrey Peters Jeffrey Peters Senior Vice President and General Counsel
2023 Q2 Q2 2023 Earnings
8-K
Filed August 9, 2023
2023
Q2
Q2 2023 Earnings
8-KFiled August 9, 2023
Aug 9, 2023 0001125345-23-000109
mgnx-202308090001125345FALSE00011253452023-08-092023-08-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 9, 2023 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 9704 Medical Center Drive Rockville,Maryland20850 (Address of Principal Executive Offices)(Zip Code) Registrant's telephone number, including area code: (301) 251-5172 Not applicable (Former Name or Former Address, if Changed Since Last Report) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.01 per share MGNXNasdaq Global Select Market Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02 Results of Operations and Financial Condition On August 9, 2023, MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the quarter ended June 30, 2023. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit NumberDescription of Exhibit 99.1 Press Release dated August 9, 2023 104Cover Page Interactive Data (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 9, 2023MACROGENICS, INC. By: /s/ Jeffrey Peters Jeffrey Peters Senior Vice President and General Counsel
2023 Q1 Q1 2023 Earnings
8-K
Filed May 9, 2023
2023
Q1
Q1 2023 Earnings
8-KFiled May 9, 2023
May 9, 2023 0001125345-23-000077
mgnx-202305090001125345FALSE00011253452023-05-092023-05-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2023 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 9704 Medical Center Drive Rockville,Maryland20850 (Address of Principal Executive Offices)(Zip Code) Registrant's telephone number, including area code: (301) 251-5172 Not applicable (Former Name or Former Address, if Changed Since Last Report) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.01 per share MGNXNasdaq Global Select Market Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02 Results of Operations and Financial Condition On May 9, 2023, MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the quarter ended March 31, 2023. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit NumberDescription of Exhibit 99.1 Press Release dated May 9, 2023 104Cover Page Interactive Data (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 9, 2023MACROGENICS, INC. By: /s/ Jeffrey Peters Jeffrey Peters Senior Vice President and General Counsel
2022 Q4 Q4 2022 Earnings
8-K
Filed March 15, 2023
2022
Q4
Q4 2022 Earnings
8-KFiled March 15, 2023
Mar 15, 2023 0001125345-23-000058
mgnx-202303150001125345FALSE00011253452023-03-152023-03-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 15, 2023 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 9704 Medical Center Drive Rockville,Maryland20850 (Address of Principal Executive Offices)(Zip Code) Registrant's telephone number, including area code: (301) 251-5172 Not applicable (Former Name or Former Address, if Changed Since Last Report) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.01 per share MGNXNasdaq Global Select Market Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02 Results of Operations and Financial Condition On March 15, 2023, MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the year ended December 31, 2022. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit NumberDescription of Exhibit 99.1 Press Release dated March 15, 2023 104Cover Page Interactive Data (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 15, 2023MACROGENICS, INC. By: /s/ Jeffrey Peters Jeffrey Peters Senior Vice President and General Counsel
2022 Q3 Q3 2022 Earnings
8-K
Filed November 3, 2022
2022
Q3
Q3 2022 Earnings
8-KFiled November 3, 2022
Nov 3, 2022 0001125345-22-000103
mgnx-202211030001125345FALSE00011253452022-11-032022-11-03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 3, 2022 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 9704 Medical Center Drive Rockville,Maryland20850 (Address of Principal Executive Offices)(Zip Code) Registrant's telephone number, including area code: (301) 251-5172 Not applicable (Former Name or Former Address, if Changed Since Last Report) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.01 per share MGNXNasdaq Global Select Market Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02 Results of Operations and Financial Condition On November 3, 2022, MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the quarter ended September 30, 2022. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit NumberDescription of Exhibit 99.1 Press Release dated November 3, 2022 104Cover Page Interactive Data (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 3, 2022MACROGENICS, INC. By: /s/ Jeffrey Peters Jeffrey Peters Senior Vice President and General Counsel
2022 Q2 Q2 2022 Earnings
8-K
Filed August 8, 2022
2022
Q2
Q2 2022 Earnings
8-KFiled August 8, 2022
Aug 8, 2022 0001125345-22-000089
mgnx-202208080001125345FALSE00011253452022-08-082022-08-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2022 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 9704 Medical Center Drive Rockville,Maryland20850 (Address of Principal Executive Offices)(Zip Code) Registrant's telephone number, including area code: (301) 251-5172 Not applicable (Former Name or Former Address, if Changed Since Last Report) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.01 per share MGNXNasdaq Global Select Market Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02 Results of Operations and Financial Condition On August 8, 2022, MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the quarter ended June 30, 2022. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit NumberDescription of Exhibit 99.1 Press Release dated August 8, 2022 104Cover Page Interactive Data (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 8, 2022MACROGENICS, INC. By: /s/ Jeffrey Peters Jeffrey Peters Senior Vice President and General Counsel
2022 Q1 Q1 2022 Earnings
8-K
Filed May 3, 2022
2022
Q1
Q1 2022 Earnings
8-KFiled May 3, 2022
May 3, 2022 0001125345-22-000046
mgnx-202205030001125345FALSE00011253452022-05-032022-05-03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 3, 2022 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 9704 Medical Center Drive Rockville,Maryland20850 (Address of Principal Executive Offices)(Zip Code) Registrant's telephone number, including area code: (301) 251-5172 Not applicable (Former Name or Former Address, if Changed Since Last Report) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.01 per share MGNXNasdaq Global Select Market Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02 Results of Operations and Financial Condition On May 3, 2022, MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the quarter ended March 31, 2022. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit NumberDescription of Exhibit 99.1Press Release dated May 3, 2022 104Cover Page Interactive Data (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 3, 2022MACROGENICS, INC. By: /s/ Jeffrey Peters Jeffrey Peters Senior Vice President and General Counsel
2021 Q4 Q4 2021 Earnings
8-K
Filed February 24, 2022
2021
Q4
Q4 2021 Earnings
8-KFiled February 24, 2022
Feb 24, 2022 0001125345-22-000014
mgnx-202202240001125345FALSE00011253452022-02-242022-02-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 24, 2022 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 9704 Medical Center Drive Rockville,Maryland20850 (Address of Principal Executive Offices)(Zip Code) Registrant's telephone number, including area code: (301) 251-5172 Not applicable (Former Name or Former Address, if Changed Since Last Report) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.01 per share MGNXNasdaq Global Select Market Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02 Results of Operations and Financial Condition On February 24, 2022, MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the year ended December 31, 2021. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit NumberDescription of Exhibit 99.1 Press Release dated February 24, 2022 104Cover Page Interactive Data (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 24, 2022MACROGENICS, INC. By: /s/ Jeffrey Peters Jeffrey Peters Senior Vice President and General Counsel
2021 Q3 Q3 2021 Earnings
8-K
Filed November 2, 2021
2021
Q3
Q3 2021 Earnings
8-KFiled November 2, 2021
Nov 2, 2021 0001125345-21-000114
mgnx-202111020001125345FALSE00011253452021-11-022021-11-02 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 2, 2021 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 9704 Medical Center Drive Rockville,Maryland20850 (Address of Principal Executive Offices)(Zip Code) Registrant's telephone number, including area code: (301) 251-5172 Not applicable (Former Name or Former Address, if Changed Since Last Report) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.01 per share MGNXNasdaq Global Select Market Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02 Results of Operations and Financial Condition On November 2, 2021, MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the quarter ended September 30, 2021. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit NumberDescription of Exhibit 99.1 Press Release dated November 2, 2021 104Cover Page Interactive Data (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 2, 2021MACROGENICS, INC. By: /s/ Jeffrey Peters Jeffrey Peters Vice President and General Counsel
2021 Q2 Q2 2021 Earnings
8-K
Filed July 29, 2021
2021
Q2
Q2 2021 Earnings
8-KFiled July 29, 2021
Jul 29, 2021 0001125345-21-000100
mgnx-202107290001125345FALSE00011253452021-04-292021-04-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 29, 2021 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 9704 Medical Center Drive Rockville,Maryland20850 (Address of Principal Executive Offices)(Zip Code) Registrant's telephone number, including area code: (301) 251-5172 Not applicable (Former Name or Former Address, if Changed Since Last Report) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.01 per share MGNXNasdaq Global Select Market Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02 Results of Operations and Financial Condition On July 29, 2021, MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the quarter ended June 30, 2021. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit NumberDescription of Exhibit 99.1 Press Release dated July 29, 2021 104Cover Page Interactive Data (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 29, 2021MACROGENICS, INC. By: /s/ Jeffrey Peters Jeffrey Peters Vice President and General Counsel
2021 Q1 Q1 2021 Earnings
8-K
Filed April 29, 2021
2021
Q1
Q1 2021 Earnings
8-KFiled April 29, 2021
Apr 29, 2021 0001125345-21-000061
mgnx-202104290001125345FALSE00011253452021-04-292021-04-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 29, 2021 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 9704 Medical Center Drive Rockville,Maryland20850 (Address of Principal Executive Offices)(Zip Code) Registrant's telephone number, including area code: (301) 251-5172 Not applicable (Former Name or Former Address, if Changed Since Last Report) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.01 per share MGNXNasdaq Global Select Market Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02 Results of Operations and Financial Condition On April 29, 2021, MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the quarter ended March 31, 2021. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit NumberDescription of Exhibit 99.1 Press Release dated April 29, 2021 104Cover Page Interactive Data (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 29, 2021MACROGENICS, INC. By: /s/ Jeffrey Peters Jeffrey Peters Vice President and General Counsel
2020 Q4 Q4 2020 Earnings
8-K
Filed February 25, 2021
2020
Q4
Q4 2020 Earnings
8-KFiled February 25, 2021
Feb 25, 2021 0001125345-21-000034
mgnx-202102250001125345FALSE00011253452020-06-162020-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 25, 2021 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware001-3611206-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number)(IRS Employer Identification No.) 9704 Medical Center Drive Rockville,Maryland20850 (Address of Principal Executive Offices)(Zip Code) Registrant's telephone number, including area code: (301) 251-5172 Not applicable (Former Name or Former Address, if Changed Since Last Report) Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.01 per shareMGNXNasdaq Global Select Market Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02 Results of Operations and Financial Condition On February 25, 2021, the Company announced financial and operating results as of and for the year ended December 31, 2020. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01Financial Statements and Exhibits (d) Exhibits. Exhibit NumberDescription of Exhibit 99.1 Press Release dated February 25, 2021 104Cover Page Interactive Data (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MACROGENICS, INC. Date: February 25, 2021 By:/s/ Jeffrey Peters Jeffrey Peters Vice President and General Counsel
Latest MacroGenics Inc. News
MGNX Breaking Stock News: Dive into MGNX Ticker-Specific Updates for Smart Investing
GlobeNewswire
MacroGenics to Participate in Upcoming Investor Conferences
📊
AI Sentiment
Positive
6/10
Compare MGNX vs Leading Stocks
See how MGNX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "MGNX MacroGenics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.